Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...

In India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

Indian businesses brace for 2026-27 with geopolitical tensions and AI reshaping industries. While core sectors show stability, policy shift...

India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...

The EU-India FTA promises cheaper drugs and medical devices, but India's regulatory framework may hinder patient benefits. Current pricing ...

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimi...

Dr Reddy's shares: The company posted a 14% year-on-year decline in consolidated net profit to Rs 1,210 crore.

Indian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting...

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...

Indian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's ...

Brokerages stay bullish: Nuvama starts Eureka Forbes with Buy (20% upside), Motilal Oswal reaffirms Biocon Buy (13% upside), Religare Broki...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...

The Indian pharmaceutical sector is poised for growth, driven by government support for R&D and manufacturing. Policies promoting bulk drug...